OakChart

Enlivex Ltd

ENLVHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 8:15 AM ET

1.22+0.02 (1.67%)
2026-11-11 14:26 CET
Market cap
1.84 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
1,891.61 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
1,565.47
P/E
0.00
Compare

Price

ENLV against its 20, 50 and 200-day averages
2050200beatearnings
0.00100.00200.001.0M2.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENLVclose 1.2220-day 2.2950-day 7.13200-day 129.371.22

99.7% under 434.40 on 24 Nov 2025. Last 15 sessions, 173.2% high to low

Profile

ENLV
52-week range, 0% of the way up
1.20434.4

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Employees34
IPOJul 31, 2014
Beta1.64
ATR, 14d0.58
Rel volume0.48
Short float14.14%
Insider own89.54%
Inst own1.09%

Snapshot

6 groups

Valuation

Index-
Market Cap1.87M
Enterprise Value13.78M
Income1.24B
Sales0.00M
Book/sh3705.56
Cash/sh3.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees34
IPOJul 31, 2014

Ratios

P/E0.00
Forward P/E-
PEG-
P/S-
P/B0.00
P/C0.33
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio119.39
Current Ratio119.39
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)6113.99
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM3852.02%
Sales Y/Y TTM-
EPS Q/Q4589.50%
Sales Q/Q-
EarningsAug 24
EPS/Sales Surpr.0.00% -

Ownership

Insider Own89.54%
Insider Trans0.00%
Inst Own1.09%
Inst Trans-
ROA104.94%
ROE126.17%
ROIC31.69%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-46.71%
SMA50-82.88%
SMA200-99.06%
Trades-

Technical

Shs Outstand1.05M
Shs Float0.16M
Short Float14.14%
Short Ratio0.32
Short Interest0.02M
52W High434.40 -99.72%
52W Low1.20 1.67%
Volatility9.93% 14.64%
ATR (14)0.58
RSI (14)13.82
Beta1.64
Rel Volume0.48
Avg Volume69.78K
Volume1,668

Performance

Perf Week-12.23%
Perf Month-65.71%
Perf Quarter-95.49%
Perf Half Y-99.31%
Perf YTD-99.28%
Perf Year-99.51%
Perf 3Y-99.72%
Perf 5Y-99.94%
Perf 10Y-99.99%
Recom1.00
Target Price1280.00
Prev Close1.20
Price1.22
Change %1.67%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Mar 02, 2021ReiteratedHH.C. WainwrightBuy$22 → $33+2,604.9%

Peers

Mkt cap
TickerCompanyMkt cap
LGVNLongeveron Inc9.24M
PLURPluri Inc14.12M
CELZCreative Medical Technology Holdings Inc4.49M
BRTXBioRestorative Therapies Inc2.15M
MESOMesoblast Ltd ADR1.82B
NCELNewcelX Ltd15.72M
CELUCelularity Inc23.07M
BCDABioCardia Inc15.14M
LCTXLineage Cell Therapeutics Inc263.02M
ICUSeaStar Medical Holding Corp10.31M

News

latest 14 of 206
  • Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response (GlobeNewswire) -20.79%
  • Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
  • Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal (GlobeNewswire)
  • Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 (GlobeNewswire) -12.95%
  • Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
  • Loading…
  • Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens (GlobeNewswire) -6.70%
  • Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June (GlobeNewswire) -13.33%
  • Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones (GlobeNewswire)
  • Enlivex Announces $400,000,000 Private Placement (GlobeNewswire) -47.42%
  • Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion (GlobeNewswire)
  • Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra in Age-Related Knee Osteoarthritis (GlobeNewswire)
  • Exclusive: FDA grants RMAT designation to Enlivexs Allocetra for knee OA (Investing.com)
  • Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-24-4.960-4.9601,5650.000.001
2026Q12026-05-22-4.960-4.800-34.5600.000.001
2025Q42026-03-25-34.224-20.7126,1900.000.002
2025Q32025-12-01-28.080-31.680-22.0080.000.002
2025Q22025-08-18-27.048-34.896-18.7920.000.001
2025Q12025-05-23-35.256-36.840-34.8700.000.002
2024Q42025-02-26-37.512--52.5240.00--
2024Q32024-12-02-38.400-38.400-29.350-0.001
2024Q22024-08-19-28.800-52.800-38.0160.00-1
2024Q12024-05-24-55.200-60.000-53.0570.00-1
2023Q42024-02-28-117.6-67.200-117.37--1
2023Q32023-11-20-76.800-76.800-76.954--1
2023Q22023-08-07-88.800-103.2-87.710--1
2023Q12023-06-26-93.600-96.000-93.557--1
2022Q42023-04-04-93.600-91.200-93.6580.00-1
2022Q12022-12-19-98.400-98.400-107.460.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY-10,368-9,408-10,3680.000.00
2016FY-9,696-10,080-9,696-0.00
2019FY-254.4-254.4-260.38--
2020FY-216-172.8-215.48--
2021FY-194.4-206.4-194.42--
2022FY-405.6--405.24--
2023FY-374.4-326.4-375.59--
2024FY-155.45-156-154.90.000.00
2025FY-138.91-94.8006,1140.000.00
2026FY--19.200--0.00
2027FY--21.600--0.00
2028FY--226.22---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-241000.000.000.00
2026Q3S2026-05-221000.000.000.00
2026Q3S2026-04-061000.000.000.00
2026Q3S2025-12-071000.000.000.00
2026Q3S2025-12-012000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00
2026Q3S2025-11-052000.000.000.00
2026Q3S2025-11-042000.000.000.00
2026Q3S2025-11-032000.000.000.00
2026Q3S2025-11-022000.000.000.00
2026Q3S2025-11-012000.000.000.00

Estimate history

EPS, annual-3436.8-2681.395-260.381-215.484-194.422-405.242-375.586-175.6546114.0936113.9949
Period201720182019202020212022202320242025TTM
EPS, quarterly-53.057-38.016-29.35-52.524-34.87-18.792-22.0086189.6651565.472
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26
Shares, annual0.0020.0020.0430.0610.0760.0770.0770.0990.9891.052
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0780.0870.0920.0990.0990.0990.1010.9891.052
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.330.550.840.780.550.290.300.12
Gross Profit-0.06-0.33-0.55-0.83-0.78-0.55-0.29-0.30-0.12
Selling, General and Administrative Excl. Other4.1814.6714.9924.0923.8117.728.287.245.18
Research and Development2.928.9210.1317.9916.7511.324.604.444.13
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.23-15.00-15.54-24.93-24.59-18.27-8.57-7.54-5.30
Interest Expense1.330.010.010.01-0.330.010.010.00
Unusual Expense-2,467.94-1,632.400.000.001.980.000.000.05-0.13
Net Income Before Taxes2,458.311,618.17-15.01-29.07-31.06-14.47-11.82-9.38-4.24
Income Taxes566.70382.650.000.000.000.000.000.000.00
Consolidated Net Income1,891.611,235.53-15.01-29.07-31.06-14.47-11.82-9.38-4.90
Net Income From Continuing Operations1,891.611,235.53-15.01-29.07-31.06-14.47-11.82-9.38-4.90
Net Income1,891.611,235.53-15.01-29.07-31.06-14.47-11.82-9.38-4.90
EPS (Recurring)135.77459.45-175.65-375.59-387.13-194.42-215.48-259.39-2,731.94
EPS (Basic, Before Extraordinaries)1,829.766,489.09-175.65-375.59-405.24-194.42-215.48-260.38-2,681.40
EPS (Diluted)1,565.476,114.09-175.65-375.59-405.24-194.42-215.48-260.38-2,681.40
EBITDA-4.17-14.67-14.99-24.09-23.81-17.72-8.28-7.24-5.18
Non-Operating Income (Expense)-4.070.780.54-4.13-4.494.13-3.25-1.790.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-0.66
Stock Option Compensation Expense0.121.412.071.952.712.910.670.811.01
Shares Outstanding1.050.990.100.080.080.080.060.040.00
Market Capitalization1.841.8427.6750.2272.50114.57122.9886.722.60

Income statement, quarterly

Currency USD, millions
Metric2026Q22025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.080.080.090.090.040.160.16
Gross Profit-0.06-0.08-0.08-0.09-0.09-0.04-0.16-0.16
Selling, General and Administrative Excl. Other4.185.792.482.993.415.452.962.83
Research and Development2.923.031.482.142.553.422.352.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.23-5.86-2.56-3.08-3.50-5.48-3.12-2.99
Interest Expense1.33-0.000.000.000.000.000.00
Unusual Expense-2,467.94-1,632.400.000.000.000.000.000.00
Net Income Before Taxes2,458.311,625.70-2.21-1.87-3.45-5.18-2.60-3.10
Income Taxes566.70382.650.000.000.000.000.000.00
Consolidated Net Income1,891.611,243.05-2.21-1.87-3.45-5.18-2.60-3.10
Net Income From Continuing Operations1,891.611,243.05-2.21-1.87-3.45-5.18-2.60-3.10
Net Income1,891.611,243.05-2.21-1.87-3.45-5.18-2.60-3.10
EPS (Recurring)135.77499.79-22.01-18.79-34.87-52.52-29.35-38.02
EPS (Basic, Before Extraordinaries)1,829.766,564.66-22.01-18.79-34.87-52.52-29.35-38.02
EPS (Diluted)1,565.476,189.66-22.01-18.79-34.87-52.52-29.35-38.02
EBITDA-4.17-5.79-2.48-2.99-3.41-5.45-2.96-2.83
Non-Operating Income (Expense)-4.07-0.840.351.210.050.500.52-0.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.120.540.280.300.290.920.380.39
Price To Earnings Ratio-0.03------
Shares Outstanding1.050.990.100.100.100.100.090.09
Market Capitalization1.84166.9325.2626.7223.1427.6736.9426.71

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.8723.6127.4350.2484.2436.9613.519.783.53
Short Term Receivables0.231.230.000.000.000.002.400.210.03
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1,737.081.156.332.092.201.160.510.290.07
Total Current Assets1,743.1825.9933.7652.3386.4438.1216.4210.283.62
Net Property, Plant & Equipment0.941.152.5814.908.222.141.060.69-
Total Investments and Advances0.370.330.310.310.320.090.080.060.00
Long-Term Note Receivable0.000.21-------
Intangible Assets582.510.000.000.000.000.000.000.000.00
Other Assets0.000.010.180.100.160.010.010.020.00
Total Assets2,327.0027.6936.8367.6495.1540.3617.5611.033.62
Short Term Debt Incl. Current Port. of LT Debt0.260.230.350.650.620.200.120.000.00
Accounts Payable3.810.810.831.950.880.460.320.170.02
Income Tax Payable-------0.22-
Other Current Liabilities4.962.754.894.013.223.715.540.730.44
Total Current Liabilities9.023.806.066.614.724.375.981.130.46
Long Term Debt0.380.300.694.195.390.500.300.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.01-
Deferred Tax Liabilities382.65--------
Other Liabilities0.000.000.000.000.000.000.000.190.00
Total Liabilities392.054.106.7510.8010.114.876.281.330.46
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.520.00
Common Equity1,934.9523.5930.0856.8485.0435.4911.289.183.16
Total Shareholders Equity1,934.9523.5930.0856.8485.0435.4911.289.713.16
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,934.9523.5930.0856.8485.0435.4911.289.713.16
Total Liabilities & Stockholders Equity2,327.0027.6936.8367.6495.1540.3617.5611.033.62
Book Value Per Share1,956.29239.37388.21740.521,113.35583.83262.015,023.481,816.38
Tangible Book Value Per Share1,367.36239.37388.21740.521,113.35583.83262.015,023.481,816.38
Full-Time Employees3436-777150-312
Price to Book Ratio0.001.171.291.151.353.477.691.672.04
Return on Assets104.94-46.54-55.65-38.16-21.35-40.83-65.64-66.88-83.43
Return on Equity126.17-55.95-66.88-43.78-24.01-50.56-89.42-76.17-100.24
Return on Invested Capital63.84-62.85-94.47-50.89-16.00-32.86-81.04-50.49-188.01
Quick Ratio193.246.845.577.9218.328.722.759.097.87
Current Ratio193.246.845.577.9218.328.722.759.097.87

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1,235.53-15.01-29.07-31.06-14.47-11.82-9.38-4.24
Depreciation-0.330.550.840.780.550.290.210.12
Deferred Taxes & Investment Tax Credit-382.650.000.000.000.000.000.000.00
Other Funds (Non Cash)--1,629.742.686.535.53-2.260.841.100.88
Funds from Operations--11.23-11.79-21.71-24.76-16.19-10.70-8.08-3.24
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.82-1.22-1.820.80-1.36-0.311.040.08
Cash from Operating Activities--10.42-13.01-23.52-23.95-17.54-11.01-7.04-3.16
Capital Expenditures--19.57-0.10-0.24-8.12-1.63-1.02-0.19-0.46
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-1.382.290.130.000.000.001.55-
Purchase or Sale of Investments-16.876.87-25.8770.65-36.78-19.96-7.71-0.07
Purchase of Investments--24.50-32.37-26.17-1.61-104.42-19.96-7.71-0.07
Sale Or Maturity of Investments-41.3739.240.3072.2567.63--0.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--1.329.06-25.9762.52-38.41-20.98-6.36-0.53
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Change in Capital Stock-10.386.450.360.1560.9833.088.315.19
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-10.386.450.360.1560.9833.088.315.19
Proceedsfrom Stock Options-10.386.450.360.0053.1724.470.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-10.386.450.360.1560.9833.088.315.19
Exchange Rate Effect---0.000.00-0.410.390.83-0.77
Net Change in Cash--1.362.51-49.1338.724.621.49-4.270.73
Free Cash Flow--10.48-13.11-23.76-32.08-19.17-12.03-7.23-3.62

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments5.635.8718.3219.6220.6623.61
Short Term Receivables0.030.230.570.891.131.23
Inventories0.000.000.000.000.000.00
Other Current Assets3,745.351,737.080.610.810.851.15
Total Current Assets3,751.001,743.1819.5021.3222.6525.99
Net Property, Plant & Equipment0.840.941.080.921.071.15
Total Investments and Advances0.410.370.360.350.320.33
Intangible Assets1,146.81582.510.000.000.000.00
Other Assets0.910.000.000.000.000.01
Total Assets4,899.972,327.0020.9422.6024.0427.69
Short Term Debt Incl. Current Port. of LT Debt17.170.260.280.260.240.23
Accounts Payable1.693.810.380.540.530.81
Other Current Liabilities12.554.962.382.522.372.75
Total Current Liabilities31.429.023.033.333.143.80
Long Term Debt0.370.380.430.220.260.30
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities969.94382.65----
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1,001.73392.053.463.543.414.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3,898.241,934.9517.4819.0520.6323.59
Total Shareholders Equity3,898.241,934.9517.4819.0520.6323.59
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3,898.241,934.9517.4819.0520.6323.59
Total Liabilities & Stockholders Equity4,899.972,327.0020.9422.6024.0427.69
Book Value Per Share3,705.561,956.29172.70191.67207.57239.37
Tangible Book Value Per Share2,615.441,367.36172.70191.67207.57239.37
Full-Time Employees-34---36
Price to Book Ratio0.000.091.451.401.121.17
Return on Assets-104.94-50.07-48.07-52.02-46.54
Return on Equity-126.17-57.64-55.02-60.35-55.95
Return on Invested Capital48.5264.23-12.31-9.69-16.52-21.67
Quick Ratio119.39193.246.436.417.206.84
Current Ratio119.39193.246.436.417.206.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q22025Q42025Q32025Q22025Q12024Q4
Net Income-1,318.27-2.53-1.89-3.45-5.20
Depreciation-0.080.090.090.090.04
Other Funds (Non Cash)--1,728.450.330.41-0.790.39
Funds from Operations--4.26-2.10-1.39-4.15-4.78
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-1.36-0.200.17-0.470.67
Cash from Operating Activities--2.90-2.30-1.22-4.62-4.11
Capital Expenditures--20.69-0.02-0.01-0.03-0.04
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.510.360.250.340.30
Purchase or Sale of Investments-10.353.830.852.873.11
Purchase of Investments--1.65-7.38-7.41-9.54-1.24
Sale Or Maturity of Investments-12.0011.218.2612.414.35
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--9.834.161.093.173.37
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-10.440.380.000.201.28
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-10.440.380.000.201.28
Proceedsfrom Stock Options-11.010.00-0.200.201.27
Issuance or Reduction of Debt, Net-0.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.00
Cash from Financing Activities-10.440.380.000.201.28
Net Change in Cash--2.292.24-0.13-1.250.54
Free Cash Flow--2.91-2.32-1.23-4.66-4.15

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.14%0.0M0.2M66.55K
2026-10-157.66%0.0M0.1M63.65K
2026-09-305.39%0.0M0.1M21.91K
2026-09-152.63%0.0M0.1M15.65K
2026-08-316.55%0.0M0.1M13.07K
2026-08-148.54%0.0M0.1M10.64K
2026-07-317.25%0.0M0.2M7.59K
2026-07-151.08%0.0M0.2M2.09K
2026-06-304.30%0.0M0.1M1.78K
2026-06-150.99%0.0M0.1M2.51K
2026-05-291.31%0.0M0.1M2.39K
2026-05-151.28%0.0M0.1M2.25K
2026-04-301.70%0.0M0.1M2.35K
2026-04-151.73%0.0M0.1M2.36K
2026-03-310.23%0.0M1.0M2.26K
2026-03-130.22%0.0M1.0M1.70K
2026-02-270.24%0.0M1.0M2.39K
2026-02-130.22%0.0M1.0M16.87K
2026-01-300.23%0.0M0.9M16.68K
2026-01-150.09%0.0M0.9M16.20K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-026-K/A2026-10-02SEC
2026-10-016-K/A2026-09-30SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-08-17424B3SEC
2026-08-13EFFECTEffectiveness filing by commission orderSEC
2026-08-13SCHEDULE 13GSEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-06F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-07SEC
2026-06-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-24SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-18SEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC
2026-05-01424B3SEC
2026-04-30EFFECTEffectiveness filing by commission orderSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARK Investment Management LLC0.99%
PRELUDE CAPITAL MANAGEMENT, LLC0.13%
BANK OF AMERICA CORP /DE/0.08%
TWO SIGMA INVESTMENTS, LP0.08%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.07%
Persistent Asset Partners Ltd0.06%
RENAISSANCE TECHNOLOGIES LLC0.06%
GEODE CAPITAL MANAGEMENT, LLC0.05%
JPMORGAN CHASE & CO0.05%
SIMPLEX TRADING, LLC0.05%

Funds

Fund% owned
ARK Israel Innovative Technology ETF0.74%
Fidelity Nasdaq Composite Index Fund0.06%
Invesco NASDAQ Future Gen 200 ETF0.03%

OakChart. ENLV. Cached 15 minutes.

Some panels did not load: insider.